This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a randomised, prospective controlled trial that was carried out at a managed care organisation in Colorado, USA. Allocation of patients to the study groups was based on a computer-generated random numbers table. Study assignments were placed in envelopes that were opened on completion of the baseline visit. The overall length of followup was 12 months, but the primary outcome was also assessed at 6 months. Data on some patients were not available due to loss to follow-up (60 in the intervention group and 80 in the control group), lack of efficacy, adverse events and protocol violations. However, patients were considered in the final analysis if they had received at least one dose of study medication (for those in the intervention group) or if they had a body weight recorded at least 4 weeks after randomisation. No blinding was used.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. It included 281 patients in the intervention group and 220 in the control group. The outcome measures used were weight loss at 12 months and percentage change in weight. The study groups were not well matched at baseline. For example, of the evaluable patients, those assigned to the sibutramine plus WMP group were significantly older and had higher BMI values than those receiving the WMP alone.
Effectiveness results
The mean weight loss at 12 months was 13.7 (+/-15.0) pounds (range: -85 -20) in the intervention group and 5 (+/-13.2) pounds (range: -79 -20) in the control group, (p<0.001).
The percentage change in weight was -6% (+/-6.7) in the intervention group versus -2.2% (+/-5.5) in the control group, (p<0.001).
In the control group, 80.9% of participants had a weight loss of less than 5%, compared with 52.7% for those assigned to the intervention group.
In contrast, 19.6% of the intervention group had a weight loss of at least 10%, compared with 10% of those in the control group.
Clinical conclusions
The effectiveness analysis showed that sibutramine plus a WMP was significantly more effective than a WMP alone in terms of weight loss.
Measure of benefits used in the economic analysis
The summary benefit measure used was the mean change in body weight and the percentage change in weight. These were derived directly from the effectiveness analysis.
Direct costs
The analysis of costs was carried out from the perspective of a managed care organisation. It included the costs of outpatient visits (including medical office and emergency department visits), hospitalisations, professional services claims (e.g. oxygen, ambulance, outside physician referrals), and prescription medications. The quantities of resources used were presented for the majority of items but unit costs were, in general, not provided. Resource use was estimated using data retrieved from electronic medical records, and administrative claim and clinical databases maintained and used by the managed care organisation. Resource consumption referred to a 24-month period, including the 12 months before and after study enrolment.
The costs were estimated using Medicare's resource-based relative value scale fee schedule and the reimbursement rates of diagnosis-related groups. The costs for professional claims were based on billed amounts. The prescription costs came from average wholesale prices. An expert panel comprising 3 to 5 physicians, 2 clinical pharmacists, and a health promotion specialist determined whether outpatient visits and hospitalisations were related to obesity for the 12 months before and 12 months after study enrolment. This allowed the calculation of obesity-related health care resource consumption. All costs were updated to 2004 values using the Consumer Price Index. Discounting was not applied as the costs were incurred within 2 years.
Statistical analysis of costs
The Wilcoxon rank sum test was used to test the statistical significance of resource use and cost-differences. A regression analysis was also carried out to isolate the effect of the medications and cost of therapy while controlling for other factors.
Indirect Costs
The indirect costs were not included in the cost analysis.
Currency
US dollars ($).
Sensitivity analysis
Univariate analyses were performed on clinical and economic variables, and non-parametric statistical procedures were used for variables that were not normally distributed. A multivariate sensitivity analysis was also carried out to determine the strongest predictors of total health care costs. For incremental cost-effectiveness ratios, a non-parametric bootstrap with 1,000 replications was performed.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The health care costs were significantly greater for the sibutramine plus WMP group, compared with the WMP only group, for obesity-related physician visits, total prescriptions, obesity-related prescriptions, total health care expenditures and obesity-related health care expenditures.
Since these comparisons reflect differences between the groups without controlling for baseline differences, the authors stated that it may not be appropriate to draw conclusions on the basis of these findings. Thus, the cost analysis focused on the magnitude of the change from 12 months before enrolment to 12 months after enrolment.
There were no differences in overall health care resources used in outpatient visits, hospitalisations, or professional service claims from 12 months before enrolment to 12 months after enrolment in both groups. However, as expected, the intervention group had a greater change in prescription medication than the control group (median change: 9 versus 2; p<0.001).
The median change in total costs was $1,279 (range: 2,399 -131,090) in the intervention group and $271 (range: -4,217 -63,840) in the control group, (p<0.001).
Similar results were obtained when obesity-related costs were considered. The median change in obesity-related costs was $408 (range: -6,077 -4,868) in the intervention group and $31 (range: -6,091 -3,519) in the control group, (p<0.001).
Synthesis of costs and benefits
Average and incremental cost-effectiveness ratios (ICERs) were calculated to combine the costs and benefits.
The average cost per each pound of weight loss was $32 for sibutramine plus the WMP and $12 for the WMP alone.
The mean ICER of sibutramine plus WMP over the WMP alone was $44 (95% confidence interval, CI: 44 -46; median 42) per additional pound lost when obesity-related costs were divided by weight loss.
The ICER was $101 (95% CI: 99 -102) per additional percentage change in body weight when obesity-related costs were divided by the percentage weight loss.
The ICER was $194 (95% CI: 188 -200) when total health care costs were divided by the weight loss and $399 (95% CI: 391 -406) when divided by the percentage weight loss.
In the multivariate analysis, the strongest predictor of total health care costs was the study arm, with those participants receiving sibutramine plus WMP having an estimated annual cost of $474 more than those in the control group, (p<0.001). Interaction terms were evaluated in the model but were not significant. The univariate analysis suggested that the ICER was sensitive to changes in the price of sibutramine.
